MUC1 and lung carcinoma: TAs, such as Survvin, VEGFR (vascular endothelial growth factor receptor), MUC1 (mucin 1) and TTK (TTK protein kinase), were used most extensively as targets for developing peptide‐based therapeutic cancer vaccines, targeting lung cancer, gastrointestinal cancer and melanoma (Figure 2).